Trials / Recruiting
RecruitingNCT06509334
Trial of JYB1904 in Chronic Spontaneous Urticaria.
A Multicenter, Randomized, Double-blind, Parallel-group, Active-controlled Phase II Clinical Study to Evaluate the Efficacy, Safety and Tolerability of JYB1904 Injection in Adult Patients with Chronic Spontaneous Urticaria Inadequately Controlled by H1 Antihistamines
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 135 (estimated)
- Sponsor
- Jemincare · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This Phase II Trial is Meant to Evaluate the Efficacy, Safety and Tolerability of JYB1904 Injection in Patients With Chronic Spontaneous Urticaria.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | JYB1904 | Participants will receive JYB1904 at week0 and receive placebo at week4,8,12 |
| DRUG | JYB1904 | Participants will receive JYB1904 at week0,8 and receive placebo at week4,12 |
| DRUG | Omalizumab | Participants will receive Omalizumab every 4 weeks for 12 weeks |
Timeline
- Start date
- 2024-08-04
- Primary completion
- 2026-07-15
- Completion
- 2026-07-15
- First posted
- 2024-07-19
- Last updated
- 2024-11-29
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06509334. Inclusion in this directory is not an endorsement.